Klaipedos universiteto ligonine VšĮ
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Klaipedos universiteto ligonine VšĮ is conducting research in the field of cardiovascular diseases, targeting the prevention of stroke and systemic embolism in patients with atrial fibrillation. The studies compare innovative oral anticoagulants to standard therapy to determine safety and benefit.
- Long‑term safety profile of a novel anticoagulant compared with established treatment
- Efficacy of asundexian in reducing stroke risk in atrial fibrillation
- Evaluation of major bleeding outcomes using ISTH criteria
A team of 19 investigators supports these two cardiovascular trials, contributing to improved treatment options for at‑risk patients.
Digestive System Diseases
Research at the hospital also addresses digestive system diseases, with a focus on ulcerative colitis. The goal is to determine whether new therapeutic agents provide lasting remission and safety for patients.
- Long‑term efficacy of ABT‑494 in maintaining ulcerative colitis remission
- Safety monitoring of chronic therapy in inflammatory bowel disease
- Impact on quality of life and disease activity scores
These two trials involve the same group of investigators, reflecting the site’s commitment to advancing care in both cardiovascular and gastrointestinal fields.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 14 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 77 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1Argenx2active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klaipedos universiteto ligonine VšĮ
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Feb 2021 | Nov 2025 |
IMP list
lock Showing 1 of 79 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enoxaparin Sodium | 4 | Unknown | 2023-06-26 | 2025-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.